Mission Statement
The American Autoimmune Related Diseases Association, Inc., (AARDA) is dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the socio-economic impact of autoimmunity through initiating, fostering, and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner.
Through our shared “View from the Top,” we are privileged to offer you a view of AARDA leadership, not only from “the top” but also from all levels within AARDA. Leadership means involvement—personal, organizational, educational, compassionate, collaborative. It also means constructive enthusiasm for the present and future of AARDA’s fight against the ravages of autoimmune disease.

**Here are some of the significant FY 2017 happenings.**

**ARNet has been launched.** The Autoimmune Disease Patient Registry Research Network is up and running. ARNet facilitates research in one comprehensive, central database of anonymous patient information, enabling investigators around the world to enlist patients in clinical research studies.

In addition, ARNet helps researchers answer epidemiological questions, identify trends, and track the number of patients with certain autoimmune diseases and their experience in obtaining a correct diagnosis. The ARNet database continues to grow.

**AARDA scientific symposia, under the leadership of Noel R. Rose, M.D., Ph.D., are expanding the knowledge of autoimmune disease among scientists, researchers and medical professionals.** In 2017, we presented “Cancer Immunotherapy and Autoimmune Disease” and “Infection As a Trigger for Autoimmune Diseases.”

**AARDA’s Autoimmune Summit Meeting, at the National Press Club in Washington DC, emphasized collaboration as it brought together patients, nonprofit group leaders, medical professionals and other health community personnel, plus corporate and foundation leaders for discussions on advocacy and research.**

**AARDA’s voice was heard among legislators, congressional staff, the National Institutes of Health (NIH) representatives, and other significant leaders on national and state levels. We spoke out about the renewal of the Prescription Drug User Fee Act (PDUFA), Fastercures legislation (which was signed by the President), and the need for patients to have access to specialists.**

We spoke out on the subject of biosimilar naming; step therapy (trying potentially less effective medication before being allowed to receive more effective, admittedly expensive, treatments); access to and cost of medicines; and non-medical switching of prescriptions, the changing of prescriptions by a third party without the doctor’s knowledge. This not only can be dangerous but also can impact the doctor-patient relationship.

We continue to collaborate with national autoimmune disease-specific organizations through the National Coalition of Autoimmune Patient Groups (NCAPG), which was organized in 1998 and is facilitated by AARDA. With a current membership of 38 member groups, NCAPG lends its voice for autoimmune advocacy.

**What do we see for the coming year?** Plans for 2018 include the following:

- We look to develop a collaborative partnership with Allegheny Health Network and its new Autoimmunity Institute, having its hub at West Penn Hospital, in Pittsburgh, Pennsylvania. This is a major step in realizing our goal of a national autoimmune diagnostic and treatment center.

- Also, we plan to provide seed funds to initiate a critical major study on the cost of autoimmune disease and the obtaining of a diagnosis.

- We look to increase membership in the Autoimmune Partners Council, where partners in both the corporate and institutional worlds meet and share their experiences and knowledge with leaders in nonprofit organizations—largely representatives of the National Coalition of Autoimmune Patient Groups.

**AARDA’s tradition of Autoimmune Summit meetings, open to patients, medical/healthcare professionals, and interested others, will continue.** Also, more autoimmune scientific meetings are being planned.

The Board of Directors will develop a strategy for health forms to include a question on family autoimmune history—truly a first step in encouraging awareness and timely diagnosis among physicians.

We will work to increase basic autoimmune funding within the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Department of Defense (DOD), with specific language in the defense budget for autoimmune disease.

**Do we have a magic wand for all of this?** No, we have AARDA supporters, including loyal in-kind contributors and volunteers, who invest generously in AARDA’s mission, thereby helping us to spend very little on actual fundraising (see auditor’s report).

We urge you to continue with us—or join the AARDA efforts as a newcomer. It’s a life-saving cause! We thank you for your interest. The 50 Million are counting on us.
The year in autoimmunity has been a productive one in two important areas: assessment of response to therapy and mechanisms of disease.

A new strategy is emerging in our approach to assessing the efficacy of therapeutic regimens in autoimmune disease. The importance of considering patient self-assessment in the evaluation of new therapeutics has gained traction. This approach affirms the importance of quality of life as well as organ function as a meaningful outcome in medical therapies.

We have continued to explore mechanisms of disease with cellular metabolism emerging as a potentially important therapeutic target. Intervening with metabolism shows efficacy in many experimental models of autoimmune disease and has been previously employed in other patient populations as well. There is no question that we will see therapeutic trials beginning in the next few years that focus on altering the metabolism of particular immune cells as this will alter the activation profile of those cells and may thereby alter disease severity. Studies of experimental models have also revealed new pathways of immune activation which are now being explored in clinical trials. These focus on blockade of new cytokines, and already these have shown efficacy in psoriasis.

Tumor immunology promises to provide therapeutic strategies for the treatment of autoimmune disease. So-called “checkpoint inhibitors” that interfere with the pathways used by cells within the immune system to maintain quiescence have been incredibly effective in the treatment of cancer. Their use in cancer frees tumor cells, but an unexpected consequence has been the development of autoimmune disease in tumor patients. These observations have suggested that drugs that enhance the function of these checkpoints might reciprocally be effective therapy in autoimmune disease. This is an exciting avenue to pursue.

As technology advances, more and more studies are performed with human cells and tissues. This strategy promises to correct some misconceptions that have arisen with an emphasis on animal models.

It is gratifying that the National Institutes of Health (NIH) and the philanthropic community continue to recognize the power of science to improve human health. The work of the American Autoimmune Related Diseases Association (AARD A) as an advocacy organization for patients is of paramount importance in advancing a strong and innovative scientific agenda.

—Dr. Diamond heads the work of AARD A’s Scientific Advisory Board (SAB) which has members from eight countries. Each member actively participates in the work of the SAB through speaking, reviewing proposals, serving in advisory capacities, and representing AARD A as requested. These outstanding researchers and physicians form a truly working Scientific Advisory Board.

When 18 years ago I said, “Yes,” to becoming AARD A’s National Spokesperson, I had no idea what would be involved. I simply knew that autoimmunity was a cause I wanted to embrace—for the memory of my younger sister Heather who had been lost to lupus at the age of 19 and to all autoimmune patients, especially those who might be lost, like Heather, by misdiagnosis. Would my name as an actor in film, TV, and other media be effective? I had to try.

Since that beginning, I have been privileged to speak for AARD A and autoimmune disease patients in congressional briefings, at scientific meetings, in TV appearances, and for magazine and newspaper interviews. I have walked the halls on Capitol Hill with other AARD A volunteers and have told Heather’s story to patients and others. Now I speak out also for my own little daughters who have been born into an autoimmune family.

While we haven’t yet seen the cure for autoimmune disease, I am heartened by the advances in awareness throughout the general public, the medical profession, the broad health care community, and our federal government. I am proud of the influence that all of us in AARD A have had in those advances and the vital support that we have been able to generate for research—still inadequately funded—that has led to improved diagnosis and treatment.

In the meantime, these cruel, life-threatening diseases continue to wreak havoc on patients, 75 percent of whom are women, many in their childbearing years, and their families. Our work continues.

My message to readers of this annual report: Someone you know has an autoimmune disease, perhaps YOU. Please join me in reaching as many of the estimated 50 Million afflicted with autoimmune diseases as possible. Spread the message, encourage those who suffer, and support AARD A’s mission. You won’t be standing alone. We welcome you—however you choose to help.

Kellie Martin
AARD A National Spokesperson
and dedicated AARD A Volunteer
Major Accomplishments During FY 2017

Research
• Provided grants to five researchers in the "Young Investigators" program: University of California, Feinstein Institute for Medical Research, Johns Hopkins University, and (with Relapsing Polychondritis Awareness and Research Foundation) National Institutes of Health (NIH), Critical Care Medicine Department
• Contributed to the W. Harry Feinestone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, center for Autoimmune Disease Research, in memory of Mary Duplantier Dixon
• Supported the 17th Annual Meeting of the Federation of Clinical Immunology Societies (FOCiS), Chicago, Illinois
• Continued to amass funds for a National Autoimmune Diagnostic and Triage Center
• Launched the Autoimmune Registry Network (ARNet)
• Supported the Johns Hopkins University 18th Annual Autoimmunity Day

Education (Patient, Public, Scientific)
• Sponsored, cosponsored or supported the following:
  —"How to Dance in the Rain," Conference for the Autoimmune Community, Scleroderma Foundation Michigan Chapter and others, Okemos, MI
  —American College of Rheumatology Annual Meeting (AARDA staffed display booth), San Diego, CA
  —Colloquium, "Cancer Immunotherapy and Autoimmune Disease," Washington, CC
  —Symposium, "Infection As a Trigger for Autoimmune Diseases," Washington, DC
  —Congressional Briefing, "Individually Rare, Collectively Common: How Environmental Health Science Helps Us Understand and Prevent Autoimmune Disease," Washington, DC
• Presented Autoimmune Summit, "Autoimmunity: Yesterday, Today, and Tomorrow," Washington, DC
• Continued support for organizer/facilitator of AARDA scientific meetings, Noel R. Rose, M.D., Ph.D., Pathology Dept., Brigham and Women's Hospital and Harvard Medical School, Boston, MA
• Continued to make available Autoimmunity Curriculum for Elementary and Middle Teachers, at no charge to teachers
• Continued as a source of autoimmune disease information on WebMD
• Maintained social networking sites

Advocacy and Awareness
• By invitation, provided a speaker at the European Parliament of the European Union, Brussels, on establishing autoimmune disease as a disease category
• Sponsored ads on behalf of autoimmune patients concerning Prescription Drug User Fee Act (PDUFA), Fastercures legislation, and autoimmune disease patients to have access to specialists
• Continued AARDA 25th Anniversary Campaign and highlighted #AutoimmuneHeroes
• Expanded membership in the Autoimmune Partners Council
• Continued facilitation of the National Coalition of Autoimmune Patient Groups (NCAPG)
• Provided interviews and information for news media; had major advertisements and articles (or acknowledgement) in local and national publications

—AARDA Board member Michael Linn and AARDA/RP (Relapsing Polychondritis) Ambassador Kyle Marcelli, Grand Prix winning race car driver, show their support for AARD.

AARDA Autoimmune Walk leader Linda Vanhournout, of Bowling Green, KY (second from left), enjoys successful Walk results—$8,000!
Fundraising
• Continued to encourage and provide support for "grassroots fundraising," including the digital Grassroots Newsletter
• Continued to expand the Autoimmune Disease Awareness Walks schedule (New York, Virginia, Michigan, California, Kentucky, Georgia) and provide support for Virtual Walks
• Sponsored the AARDAs Annual Fund Raiser in the Greater Detroit area (an AARDAs national event)
• Sponsored gala dinner fund raiser "AARDAs Salutes Its 25 Heroes with a Taste from the Greats," Bouley Botanicals, New York, NY
• Co-sponsored with Grow Detroit's Young Talent "The Motor City Charity Fund Raiser" in conjunction with Detroit Grand Prix, Detroit, MI

Administration
• Maintained the following ratings:
  — Charity Navigator Four Star Charity
  — Better Business Wise Giving Alliance Charity
  — Best in America Certified by Independent Charities of America
  — Guidestar Platinum Participant rating.
• Continued to meet all standards of the National Health Council, Washington, DC, and continued as an NHC member group
• Maintained membership and active participation in the International Alliance of Patients' Organizations (IAPO)
• Continued standing in the Combined Federal Campaign (CFC)
• Maintained membership in the Health & Medical Research Charities of America
• Held combined management and fundraising costs at 5 percent of total expenses (compared with 25 percent acceptable for nonprofit organizations)
### AMERICAN AUTOIMMUNE RELATED DISEASES ASSOCIATION, INC.
#### STATEMENT OF FUNCTIONAL EXPENSES
For The Year Ended September 30, 2017

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Public Services</th>
<th>Education</th>
<th>$172,344</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Awareness</td>
<td>$882,400</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research</td>
<td>$521,529</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>$1,576,273</td>
<td>$122</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management and General</td>
<td>$6,190</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fundraising</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>$1,582,585</td>
<td></td>
</tr>
</tbody>
</table>

Other Expenses:

- **Wages**: 185,702
- **Professional fees**: 28,634
- **Postage and shipping**: 4,996
- **Social Security**: 0
- **Unemployment Compensation**: 0
- **Other**: 0

#### Supporting Services

- **Contributions**: 1,011,100
- **Filing fees**: 1,739
- **Equipment maintenance**: 3,113
- **Telephone**: 3,479
- **Insurance**: 1,956
- **State and national meetings**: 10,546
- **Travel**: 4,342
- **Depreciation**: 1,650
- **Utilities**: 2,433
- **Insurance—Health**: 1,956
- **Grants**: 1,500
- **Fines**: 2,205
- **Utilities**: 2,433
- **Miscellaneous**: 1,251
- **Retirement plan contributions**: 3,442
- **Website**: 9,147
- **Advertising and development**: 732

Funding—

- **Derby**: 0
- **Other**: 0
- **Board expenses**: 0
- **Professional training**: 0
- **Program services**: 0
- **Supporting services**: 0

Other Expenses:

- **Wages**: 185,702
- **Professional fees**: 28,634
- **Postage and shipping**: 4,996
- **Social Security**: 0
- **Unemployment Compensation**: 0
- **Other**: 0

#### For The Year Ended September 30, 2017

- **Net Assets, Beginning of Year**: 95,746
- **Net Assets, End of Year**: 95,746

### AMERICAN AUTOIMMUNE RELATED DISEASES ASSOCIATION, INC.
#### STATEMENT OF ACTIVITIES
For The Year Ended September 30, 2017

<table>
<thead>
<tr>
<th>Revenue and Other Support:</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>1,011,100</td>
<td>227,717</td>
<td>$1,238,817</td>
</tr>
<tr>
<td>Less: Donor designations</td>
<td>(5,000)</td>
<td>(5,000)</td>
<td>(5,000)</td>
</tr>
<tr>
<td>Net contributions</td>
<td>1,006,100</td>
<td>222,717</td>
<td>1,228,817</td>
</tr>
<tr>
<td>In-kind goods and services</td>
<td>1,582,585</td>
<td>0</td>
<td>1,582,585</td>
</tr>
<tr>
<td>Fundraising income</td>
<td>154,865</td>
<td>0</td>
<td>154,865</td>
</tr>
<tr>
<td>Interest income</td>
<td>3,675</td>
<td>0</td>
<td>3,675</td>
</tr>
<tr>
<td></td>
<td>2,747,225</td>
<td>227,717</td>
<td>2,974,942</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>95,746</td>
<td>(95,746)</td>
<td>0</td>
</tr>
<tr>
<td>Total Revenue and Other Support</td>
<td>2,842,971</td>
<td>131,971</td>
<td>2,974,942</td>
</tr>
</tbody>
</table>

Expenses:

- **Program services**: 468,672
- **Public awareness**: 1,363,184
- **Research**: 594,847
- **Interest income**: 3,675
- **Total program services**: 2,426,703

Supporting services:

- **Management and general**: 43,696
- **Fundraising**: 72,426
- **Total supporting services**: 116,122

Total Expenses: 2,542,825

Change In Net Assets: 300,146

Net Assets, Beginning of Year: 941,216

Net Assets, End of Year: $1,241,362
Major Contributors in Fiscal Year 2017

Major In-Kind Contributors
Dr. Jean-François Bach
Rita Baran-Faust
Catherine (Nona) Bear
Abby Bernstein
Carway Communications, Inc.
Dr. Patrizio Caturegli
Dr. Nicholas Chiorazzi
Simon Cices
Context DC
Crain’s Detroit Business
Dr. Maurizio Cutolo
Delta Sky
Dr. Betty Diamond
Dr. Luís A. Diaz
Dr. Robert A. Eisenberg
Dr. Stanley M. Finger
fkm-group
Dr. Eric Gershwin
Dr. Bevra Hahn
Stephanie P. Hales
Richard M. Hodge
Dr. Abid Khan
Dr. Steven A. Krilis
Mary Beth Krohel
Dr. Parviz Lalezari
Michael J. Linn
Dr. Ian R. Mackay
Kellie Martin
Media DC
Dr. Kenneth Olden
Penn Quarter Partners
Dr. Michelle Petri
Dr. Robert Phillips
Haley Ram
Dr. Noel R. Rose
Dr. Yehuda Shoefield
Lilly Stairs
Todd Graphic Design
Dr. Yaron Tomer
Dr. Hartmut Wekerle
Dr. Caroline Whitacre
Will Zrnchik

Individual, Corporate, and Foundation Donors
Contributions $20,000 and Over
Anonymous
AbbVie Inc.
Ameren USA
Estate of Barbara Gómez
Genentech, Inc.
Lilly USA, LLC
Michael & Rosalie Linn
Pfizer, Inc.
PhRMA
Takeda Pharmaceuticals USA
Contributions $5,000 thru $19,000
Bell Charitable Foundation
Earl M. & Margery C. Chapman Foundation
DTE Energy Foundation
Estate of Donald Johnson
FFARMS
Howl at the Moon Fund Raiser
Intercept Pharmaceuticals Inc.
Motor City Charity Event
Robert A. Waller Foundation
Contributions $1,000 thru $4,999
5 for the 5K Walk
Scott & Ann Barnhouse
Nona Bear
Dr. Marvin Bellin
Patricia Botsko
Macon Callicott
Ed & Judy Christian
Kellee & Keith Christian
Athea & Simon Cices
Clark Hill PLC
Competition Race Parts Inc.
Aisha Dee
Mary Deters
Dr. Luis Diaz
Elizabeth & Nigel Drepaul
Duro Dyne National Corporation
Enterprise Holdings Foundation
Facebook Fund Raisers
Genentech Commandments
Foundation, Inc.
Anne Himmel
Craig Hiedrichs
Rick & Eileen LaGrotta
Sarah Leppo
Level 10 Construction Fund Raiser
Dr. Nat & Jill Linhardt
Douglas & Marta Mayer
Daniel & Diana McCoy
Charles McDermott
Nancy Monaghan
Bruno Moschetta
Diane Moss
National Debt Relief
Phyllis Nazari
NECABA Management Group, Inc.
Palo On The Go Fund Raiser
Dr. Ann Pearson
Kenneth Pullig
Race For Relapsing Polychondritis
Raising awareness in honor of
Cara Lian Lebedda Fund Raiser
Diane & Charles Reissig Foundation
Emily Rickards Fund Raiser
Rotary District 7280 State Conference Fund Raiser
Jaclyn & Scott Selby
Diane & Ronald Shepard
South Warren High School Beta
Club, Bring in the Dough
Jane Talt
Valine Thomas
Vicki Tolan
Ann Willett
Carol Williams
Rick Wilson
Wrigley's Pharmacy
Contributions $250 thru $999
50 Cents for 50 Million
Marilyn Assiff
David Awbery
Mercedes Barris
Ballette NextGen’s Bowling for
Charity event
Orlando Belotti
Elaine Belter
Carolyn Bennett
Bobby & Kerry Benson
Sandra Bookman
Tami Brown
Terence & Ana Carter
Lynn Carver
Stanley & Jeanne Cavitt
Marybeth Champion-Garthe
Marllyn Clague
Karen Clark
Angela Clarke
Kate Cleary-Benchen
Leah Collins
Coryngham Family Charitable
Foundation
Pamela Cotton
Sheila Cruz
Heidi Darrah
Robert Dembowski
Robert & Eleanor Demple
Family Foundation
Kathleen & Julie DiGregorio
Dr. Mark Donovan
Alice Dom
Andrew & Maryann Dunnet
Mark Ellis
Shrin Emami
Ashlee Espinoza
Roslyn Fanello
Patrice & James Farrell
Linda Feist & Roger Junnila
Sandra Fillbert
Judith Fillius
Dr. Stanley M. & Shelley Finger
Akiha Flesher
Dr. Herbert & Margaret Ford
Chuck & Susan Gaidica
David Goldsmith
Logan Goodrich
Doren & Alan Griffin
Mary Griffeth
Christina Hallenbeck
Judith & Charles Harris
Nancy Harris
Jason Hantaal
Mary Janis Hayden
Jeffrey & Karen Hays
Heartland Home Foods
Dr. & Mrs. Edward &
Carolyn Hecker
Jan Hewlett
Dru Hickman
Ellen Hipsky
Jasmine & Justin Jacob
Sharon Jacobs & David Cohan
Thomas Jameson
Barbara Jones
Geoffrey Karmy
Joy Kavanaugh
Patti Keeley
Roy Kelley
Steve & Lynn Kieffer
Khalil Foundation
Taylor Kittleman
Jill Kiviat
Suzanne Klein
Rita Konetzka
Kathleen Kredor
Robert & Jerr Krueger
Heather Kupets Harris
Eileen Laird & Tom Leonard
Bezenna Leven
Karen & Joe Levine
Dana Lewis
Wade Lewis
Peggy Lichter & David DiDomenico
Lesley Lyons
Linda MacAlece
Kara Macdonald
Charles, Dawn, Sarah & Emily Mallon
Gail & John Maloney
Marsa, Noelle, William &
Eric Marold
Shannon Marold
Keith & Mary McJunke
MidMichigan Health
Katherine Morgan
Michael & Kara Mozina
Mrs. Colorado International Event
Dave Nahmias
National Christian Foundation
Colorado
Patrick Niemeyer
NYU Langone Health, Division of
Rheumatology
Diane Northern
Michelle Ouellet
William Padnos & Margery Kaye
Yitzchak Pastreich
Penn Quarter Partners LLC
Michaela Perezra
Dianne Peterson
Tracy Pierce
Mike & Mary Quinlan
RCC Manhattan Transit Authority
Sarah Ramsay
Gail Reed
Maggi Reiss
Anne Remington
Douglas & Linda Robinson
Robson & Associates
James Ryan
Gretchen Schmidt
Patrick Smith
Stanley Sobol
Sharon Speer
Art Storch
Joe & Rebecca Taylor
Jackie Thompson & Gene Frazer
Kaseem & Daniel Thornberry
Edward Tommasi
Kelly & Antonio Tourgeman
Troutman Sanders LLP
Denin &
Donations
Twitch TV Live Stream Fund Raiser
U.A.W Local 3000
Jeff & Joanne Urbanowski
James, Linda, Jim, Jacob, Andrew
& Matthew Vanhourout
Dennis Weiss
Shirley Wesley
Carol Lynn White
Peter Williams
Rita Wilson
Charles Wolford
Michele Wornow
Pat Wright
Karen Yager-Rizzo
Ellen Yarborough
Carole & Dave Yoho
Diane Zehnpfennig

Payroll Campaigns & Matching Gifts
AT & T
AbbVie Foundation
Allstate
American Express
BF Foundation
Boeing
Chevron Humankind
City of Seattle
Deutsche Bank Americas Foundation
GE Foundation
Gap Inc.
Give with Liberty
IBM
JP Morgan Chase
Maryland Charity Campaign
Merck
Morgan Stanley
New York Life
PepsiCo Foundation
Shell Oil Company Foundation
United Way of Central New Mexico
United Way of Greater Philadelphia &
Southern New Jersey
United Way of Ulster County
United Way of Wyoming Valley
Viking Global Foundation
VISA Givingstation
Wells Fargo

Other Contributors and Friends
Space does not allow us to include the names of all the persons and organizations
who gave their financial support to AARDa, but we want to say “Thank you”
again as we give this recognition in honor of their generosity.

Memorials and Tributes
Since it is our policy not to release amounts given for these donations,
we take this opportunity to express our appreciation again to those kind
donors. Every contribution has been acknowledged to the donors, to those
persons honored, and to the families of those held in memorial.
### Advisors to the Board

- **Edward K. Christian**
  Professor/CEO
  Saga Communications, Inc.
  Grosse Pointe Farms, Michigan

- **Howard E. Hagon**
  Owner (Retired)
  Contour Fabricators
  Swartz Creek, Michigan

- **Stephanie P. Hales**
  Partner
  Sidley Austin LLP
  Washington, DC

- **Robert Meyer, CPA**
  President
  Fort Wayne Insurance Services, Inc.
  Fort Wayne, Indiana

### National Spokesperson

- **Kellie Martin**
  Actor, Author
  Los Angeles, California

### Officers and Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>John P. Kaiser, Jr., CPA</td>
<td>Partner, RMS US, LLP, Peoria, Illinois</td>
</tr>
<tr>
<td>Michael J. Linn</td>
<td>Chief Operating Officer, Varadero Capital, LLP, New York, New York</td>
</tr>
<tr>
<td>Michelle Ouellet</td>
<td>CACI International, Vienna, Virginia</td>
</tr>
<tr>
<td>Robert H. Phillips, Ph.D.</td>
<td>Director, Center for Coping, Long Island, New York</td>
</tr>
<tr>
<td>J. Michael Quinlan, I.L.M</td>
<td>Attorney &amp; Corporate Executive, McLean, Virginia</td>
</tr>
<tr>
<td>Scott E. Selby</td>
<td>Head, Business Development, Varadero Capital, LLP, New York, New York</td>
</tr>
<tr>
<td>Lilly Stairs</td>
<td>Head, Patient Advocacy Relations, Clare Health, San Francisco, California</td>
</tr>
<tr>
<td>Maurizio Cutolo, M.D.</td>
<td>Professor, Director for Laboratory Research and Division of Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy</td>
</tr>
<tr>
<td>Luis Diaz, M.D.</td>
<td>The CE Wheeler Jr. Distinguished Professor, Professor of Rheumatology, Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</td>
</tr>
<tr>
<td>Robert A. Eisenberg, M.D.</td>
<td>Professor of Medicine Emeritus, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>M. Eric Gershwin, M.D.</td>
<td>The Jack and Donald Chan Professor of Medicine, Chief, Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California at Davis, Davis, California</td>
</tr>
<tr>
<td>Bevra H. Hahn, M.D.</td>
<td>Professor of Medicine, Vice Chair, Department of Medicine, Chief of Rheumatology, University of California, Los Angeles, California</td>
</tr>
<tr>
<td>Steven A. Kuriss, Ph.D.</td>
<td>Head, Department of Immunology, Allergy and Infectious Disease, The St. George Hospital, Kogarah, New South Wales, Australia</td>
</tr>
<tr>
<td>Parviz Lalelari, M.D.</td>
<td>Clinical Professor, Department of Medicine and Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York</td>
</tr>
<tr>
<td>Ian Reay Mackay, A.M., M.D., E.A.A.</td>
<td>Professor (Honorary), Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria, Australia</td>
</tr>
<tr>
<td>Kenneth Olden, Ph.D., Sc.D.</td>
<td>Founding Dean, School of Public Health, Hunter College, New York, New York</td>
</tr>
<tr>
<td>Michelle Petri, M.D., M.P.H.</td>
<td>Professor of Medicine, Division of Molecular and Clinical Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland</td>
</tr>
<tr>
<td>Robert H. Phillips, Ph.D.</td>
<td>Director, Center for Coping, Long Island, New York</td>
</tr>
<tr>
<td>Yehuda Shoenfeld, M.D.</td>
<td>Head, Department of Medicine ‘B’ and Center for Autoimmune Diseases, Chaim Sheba Medical Center, Affiliated to Tel-Aviv University</td>
</tr>
<tr>
<td>Yaron Tomer, M.D.</td>
<td>Anita and Jack Saltz Chair in Diabetes Research, Professor and University Chair, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York</td>
</tr>
<tr>
<td>Hartmut Weckerle, M.D.</td>
<td>HERTIE Senior Professor, Department of Neuroimmunology, Max Planck Institute for Neurobiology, Planegg-Martinsried, Germany</td>
</tr>
<tr>
<td>Caroline Whitacre, Ph.D.</td>
<td>Vice President for Research, Office of Research, Professor, Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio</td>
</tr>
</tbody>
</table>

### Scientific Advisory Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betty Diamond, M.D.</td>
<td>Professor &amp; Head, Center for Autoimmune &amp; Musculoskeletal Diseases</td>
</tr>
<tr>
<td>Noel R. Rose, M.D., Ph.D.</td>
<td>Emeritus Professor, Johns Hopkins University Senior Lecturer</td>
</tr>
<tr>
<td>Patricia Caturegli, M.D.</td>
<td>Director, Center for Autoimmune Disease Research, Bloomburg School of Public Health</td>
</tr>
<tr>
<td>Nicholas Chiorazzi, M.D.</td>
<td>Head, Karches Center for CLL Research, Professor, Molecular Medicine and Immunology, Hofstra Northwell School of Medicine, Manhasset, New York</td>
</tr>
<tr>
<td>Joseph E. Craft, M.D.</td>
<td>Professor of Medicine and Immunobiology, Chief, Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut</td>
</tr>
<tr>
<td>Maurizio Cutolo, M.D.</td>
<td>Professor, Director, Center for Autoimmune Disease Research, Bloomburg School of Public Health, Department of Molecular and Clinical Rheumatology, New York</td>
</tr>
<tr>
<td>Luis Diaz, M.D.</td>
<td>The CE Wheeler Jr. Distinguished Professor, Professor of Rheumatology, Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</td>
</tr>
<tr>
<td>Robert A. Eisenberg, M.D.</td>
<td>Professor of Medicine Emeritus, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>M. Eric Gershwin, M.D.</td>
<td>The Jack and Donald Chan Professor of Medicine, Chief, Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California at Davis, Davis, California</td>
</tr>
<tr>
<td>Bevra H. Hahn, M.D.</td>
<td>Professor of Medicine, Vice Chair, Department of Medicine, Chief of Rheumatology, University of California, Los Angeles, California</td>
</tr>
<tr>
<td>Steven A. Kuriss, Ph.D.</td>
<td>Head, Department of Immunology, Allergy and Infectious Disease, The St. George Hospital, Kogarah, New South Wales, Australia</td>
</tr>
<tr>
<td>Parviz Lalelari, M.D.</td>
<td>Clinical Professor, Department of Medicine and Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York</td>
</tr>
</tbody>
</table>

**American Autoimmune Related Diseases Association, Inc.**

**Virginia T. Ladd, President and Executive Director**

The American Autoimmune Related Diseases Association, Inc. (AARD), DBA Autoimmune Diseases Association, is a 501(c)(3) national voluntary health organization founded in 1991. AARD is a member group and meets all standards of the National Health Council, in Washington, DC, and of the Health & Medical Research Charities of America. AARD is a member group of the Combined Federal Campaign (CFC). As a Better Business Bureau Accredited Charity, AARD meets the strong and comprehensive standards of the Better Business Bureau Wise Giving Alliance. AARD carries the seal “Best in America,” certified by Independent Charities of America, and is a GuideStar Platinum Participant. AARD has a Four Star Charity rating from Charity Navigator.